Ironwood Pharmaceuticals, Inc. Repays $200 Million in Convertible Notes

On June 15, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) fully repaid its 1.50% convertible senior notes due 2026, totaling $200.0 million in aggregate principal amount, at their scheduled maturity. The repayment was funded using the Company's available cash on hand. No noteholders converted their notes, and associated capped call transactions have expired. The company has no further obligations related to these notes.